Harmony Biosciences Inc. (HRMY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Harmony Biosciences Inc. (HRMY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

36.42

-0.03 (-0.08%)

At close: Jan 14, 2025, 3:59 PM

35.50

-2.53%

Pre-market Jan 15, 2025, 05:05 AM EST

undefined% (undefined)

Bid	35.2
Market Cap	2.08B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.11
PE Ratio (ttm)	17.26
Forward PE	n/a
Analyst	Buy

Ask	58.27
Volume	318,191
Avg. Volume (20D)	748,701
Open	36.83
Previous Close	36.45
Day's Range	35.84 - 37.04
52-Week Range	28.14 - 41.61
Beta	undefined

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 19, 2020

Employees 246

Stock Exchange NASDAQ

Ticker Symbol HRMY

Website https://www.harmonybiosciences.com

Analyst Forecast

According to 8 analyst ratings, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 48.27% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Harmony Biosciences Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of $198.60M, reflecting a 17.93% YoY growth and earnings per share of 0.84, making a 15.07% increase YoY.

Why Price Moved

2 months ago · Source

-18.53%

Harmony Biosciences shares are trading lower after... Unlock content with Pro Subscription

2 months ago · Source

+16.06%

Harmony Biosciences Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

News

23 hours ago · zacks.com

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two co...

1 day ago · investors.com

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.

2 months ago · seekingalpha.com

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points

Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 r...

2 months ago · zacks.com

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 months ago · zacks.com

HRMY vs. REGN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two s...

2 months ago · seekingalpha.com

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Brennan Doyle - Head of Investor Relations Jeffrey Dayno - President...

2 months ago · zacks.com

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.63 per share a y...

2 months ago · investors.com

Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat

Harmony Biosciences stock jumped Tuesday on the biotech company's "high-quality" third-quarter beat on the back of its narcolepsy drug.

2 months ago · zacks.com

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: Should You Buy?

Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.